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ABSTRACT
Background: Transdermal patches containing tulobuterol, slow-releasing β2-agonist patches, are now widely
used in the treatment of asthma in Japan. Unlike inhalational β2-agonists, tulobuterol patches act systemically
and may modify the functional status of inflammatory cells in the peripheral circulation. The objective of this
study is to examine the effect of tulobuterol on the adhesive interaction between blood eosinophils and endo-
thelial cells．
Methods: Peripheral blood eosinophils and human umbilical vein endothelial cells (HUVEC) were pretreated
with either tulobuterol or a control medium, and adhesion of eosinophils to HUVEC was examined using an
eosinophil peroxidase assay．
Results: Spontaneous adhesion of eosinophils to resting HUVEC was not modified by tulobuterol. On the
other hand, eosinophil adhesion to IL-4 + TNFα-stimulated-HUVEC was inhibited minimally but significantly by
tulobuterol. Furthermore, both IL-5- and FMLP-activated adhesions of eosinophils to HUVEC were partially but
significantly inhibited by tulobuterol．
Conclusions: Tulobuterol can decrease adhesion of blood eosinophils to endothelial cells. This finding sug-
gests that tulobuterol patches have anti-inflammatory properties, and may therefore contribute to the treatment
of airway inflammation in asthma．
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INTRODUCTION
Eosinophils are the predominant inflammatory cells
present in asthmatic airways. An initial step in accu-
mulation of eosinophils in asthmatic airways is adhe-
sion of peripheral blood eosinophils to endothelial
cells. This process is known to involve interactions
between α-4 or β-2 integrins of eosinophils and
VCAM-1 or ICAM-1, which are immunoglobulin su-
perfamily molecules expressed on endothelial cells.1,2
The authors and Kaiser et al. reported that corti-
costeroids do not inhibit adhesion of eosinophils to
endothelial cells.3,4 On the other hand, the authors
reported that theophylline does attenuate the adhe-
sive interaction between eosinophils and endothelial
cells.5
β2-agonists are another important class of drugs
used in the treatment of asthma. The Global Initiative
for Asthma has emphasized the significance of long-
acting inhalational β2-agonists together with inhala-
tional steroids in the treatment of moderate or severe
asthma. In Japan, transdermal patches containing tu-
lobuterol , which have been developed as a slow-
releasing β 2-agonist patch preparation , are now
widely used in treatment of asthma．
Since the active ingredient of tulobuterol patches,
unlike long-acting inhalational β2-agonists, is distrib-
uted systemically in the bloodstream before exerting
its effect, this preparation is expected to affect inflam-
matory cells in the peripheral circulation andor vas-
cular endothelial cells. In the present study, we exam-
ined the effect of tulobuterol on the adhesive interac-
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tion of peripheral blood eosinophils with vascular en-
dothelial cells．
METHODS
REAGENTS
Percoll was obtained from Pharmacia (Uppsala, Swe-
den ) . Anti-CD 16 antibody-coated magnetic beads
were purchased from Miltenyl Biotec (Auburn, CA,
USA). HuMedia-EG2 was obtained from Kurabo In-
dustries, Ltd. (Osaka, Japan), and Hank’s balanced
salt solution (HBSS) and fetal bovine serum (FBS)
were obtained from Invitrogen Corporation (Grand
Island, NY, USA) and Biomedicals , Inc . (Aurora ,
Ohio, USA), respectively. Human umbilical vein en-
dothelial cells (HUVEC) from healthy humans were
obtained from Kurabo Industries , Ltd. (Osaka , Ja-
pan). Tulobuterol was provided by Abbott Japan Co.,
Ltd. Recombinant human interleukin (IL- ) 4, IL-5 and
TNF-α were purchased from R & D Systems Inc .
(Minneapolis, MN, USA). All other reagents includ-
ing formyl-methionyl-leucyl-phenylalanine ( FMLP )
were purchased from Sigma (St. Louis, MO, USA)
unless otherwise stated．
EOSINOPHIL SEPARATION
Eosinophils were isolated from peripheral blood
specimens of normal volunteers with less than 5%
eosinophils in the total leukocyte count . Subjects
ranged in age from 20 to 37 years, with an even gen-
der. Eosinophil isolation was performed using nega-
tive immunomagnetic bead selection as previously
described . 6 Briefly , heparinized blood was diluted
with HBSS without Ca2+ and centrifuged for 20 min at
700xg over 1.090 gml Percoll. Plasma, the mononu-
clear cell band, and Percoll were removed, and the
red blood cells in the pellet were lysed by hypotonic
shock. The resulting granulocytes were washed with
4℃HBSS supplemented with 2% newborn calf serum
NCS (HBSSNCS), and then incubated with anti-
CD16 antibody-coated magnetic beads for 40 min at 4
℃. The cells were filtered through a steel wool col-
umn in a magnetic field (Miltenyl Biotec) to remove
neutrophils bound to magnetic beads. CD16-negative
eosinophils (>98% purity and >99% viability) were col-
lected , washed and resuspended in HBSS supple-
mented with 5% fetal calf serum (FCS)(HBSSFCS)．
PREPARATION OF HUVEC
HUVEC (purchased from Clonetics, San Diego, CA,
USA ) were prepared as previously described . 7
Briefly, HUVEC were cultured on type IV collagen-
coated tissue culture flasks until confluent , trans-
ferred to collagen-coated 96-well-tissue culture plates,
and cultured for 24 h in 5% CO2 at 37℃. After culture,
the incubated mixture was decanted and HUVEC
were washed three times with HBSS before use．
EOSINOPHIL ADHESION TO HUVEC
Eosinophil suspensions and monolayers of HUVEC
were pre-cultured with either tulobuterol (1―100nM)
or medium control for one hour and 24 hours, respec-
tively. For the IL-4 + TNF-α―stimulated HUVEC, pre-
treatment was performed 1 hour prior to cytokine
treatment . Eosinophil adhesion to HUVEC was as-
sessed as residual eosinophil peroxidase (EPO) activ-
ity of adherent eosinophils as previously described.7,8
Briefly , eosinophils (100 μl of 1 × 105 cellsml in
HBSSFCS) were then placed onto HUVEC monolay-
ers and incubated at 37℃for 30 min in the presence
or absence of an activator. After five washes with 37
℃ HBSS, 100 μl HBSSFCS was added to the reac-
tion wells. As standards, 100 μl of serially diluted cell
suspensions (1 × 103, 3 × 103, 1 × 104, 3 × 104, and 1 ×
105 cellsml) were added to empty wells. EPO sub-
strate (1 mM o-phenylenediamine, 1 mM H2O2, and
0.1% Triton X-100 in Tris buffer , pH 8.0) was then
added to all of the wells. After a 30-min incubation in-
terval at room temperature, 50 μl of 4 M H2SO4 was
added to stop the reaction, and absorbance was meas-
ured at 490 nm. Percent eosinophil adhesion was cal-
culated from the log dose-response curve．
DETERMINATION OF EXPRESSION OF ADHE-
SION MOLECULES ON EOSINOPHILS
The expressions of adhesion molecules on eosino-
phils was examined by flow-cytometric analysis as
previously described.9 EOS were exposed to either
0.1 μM tulobuterol or buffer (HBSS5%FCS) alone for
15 min at 37℃, and then stimulated with either 100
pM IL-5 or buffer for 15 min. The cells were washed
three times and resuspended in 4℃ PBS supple-
mented with 2% BSA and 0.2% sodium azide (FACS
buffer). Cells (1 × 105100 μl ) were incubated with
FITC-conjugated mouse anti-human CD18 ( clone :
MHM23, IgG1, Dako AS, Glostup, Denmark), FITC-
conjugated mouse anti-human CD11a (clone : MHM
24, IgG1, Dako AS), phycoerythrin (PE)-conjugated
mouse anti-human C3bi (CD11b)(clone : 2LPM19c,
IgG1, Dako AS), PE-conjugated mouse anti-human
VLA-4 (CD49d)(clone : 9F10, IgG1, BD PharMingen,
San Diego, CA, USA), or PE-conjugated mouse anti-
human CD29 (clone : MAR4, IgG1, BD PharMingen)
on ice for 30 min. Similarly PE- and FITC- conjugated
mouse IgG1 (Dako AS ) were used as isotype
matched controls. Cells were then washed and resus-
pended in FACS buffer . Mean fluorescence was
measured on at least 10,000 events using FACScan
(Becton Dickinson). Relative mean fluorescence was
determined by subtraction of values for the IgG1
isotype-matched control．
DETERMINATION OF VCAM-1 AND ICAM-1 EX-
PRESSION ON HUVEC
The expression of VCAM-1 and ICAM-1 was deter-
mined by a cell-ELISA developed as previously re-
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Fig. 1 The efect of tulobuterol on spontaneous adhesion 
of eosinophils to resting HUVEC. Values are the mean ±　
S.E.M. of ten experiments. 
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Tulobuterol (nM) Fig. 2 The efect of tulobuterol on eosinophil adhesion to 
HUVEC stimulated with IL-4 + TNF-α (both at 100 pM, 24　
hrs). Adhesion was significantly atenuated by 10 to 100 nM 
tulobuterol (p<0.01). Values are the mean ± S.E.M. of ten 
experiments. 
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ported.7 Briefly, HUVEC monolayers were cultured
in 96-well tissue culture plates in the presence or ab-
sence of 0.1 mM tulobuterol for 1 hr in 5% CO2 at
37℃ and then stimulated with a combination of IL-4
and TNF-α (both at 100 pM, 24 hrs). Prior to evalu-
ation, HUVEC were washed and incubated for 30 min
at 37℃ with a blocking buffer (PBS containing 5%
NCS and 3% nonfat dry milk). The primary antibodies
(R & D Systems, Minneapolis, MN, USA), anti-ICAM-
1 (clone BBIG-I1), anti-VCAM-1 (clone BBIG-V1) or
the isotype control mouse IgG1, were added to the
wells and incubation was continued for an additional
2 hrs at 37℃. The HUVEC were again washed three
times with blocking buffer, and the secondary anti-
body (sheep antimouse IgG peroxidase conjugate )
was added to the wells. Following 2 hrs incubation,
the cells were washed three times with PBS. Detec-
tion of the peroxidase conjugate was performed in cit-
rate urea buffer using OPD as a substrate, in a fash-
ion similar to the eosinophil adhesion assay . The
VCAM-1 or ICAM-1 concentration present on cells
was expressed as absorbance at 490 nm and reported
as the actual value minus absorbance from the IgG1
isotype control．
STATISTICS
Repeated-measures ANOVA and Scheffe constants
were used for comparison in order to determine sig-
nificance. p -values less than 0.05 were considered
significant. Values shown are mean ± SEM．
RESULTS
Initial experiments were conducted to confirm
whether tulobuterol modifies the spontaneous adhe-
sion of eosinophils to resting HUVEC. The spontane-
ous adhesion of eosinophils to resting HUVEC was
not modified by tulobuterol at concentrations up to
100 nM (Fig. 1).
When HUVEC were stimulated with IL-4 + TNF-α
to upregulate the expression of adhesion molecules,
the percentage of spontaneous adhesion of eosino-
phils to activated HUVEC was 37.4 ± 3.9% in the ab-
sence of tulobuterol , which was higher than that
noted with resting HUVEC, and was decreased to
31.4 ± 2.6% and 32.6 ± 3.2% in the presence of tu-
lobuterol at concentrations of 10 and 100 nM, respec-
tively ( p < 0.01, n = 10, Fig. 2)．
Percentage adhesion of 100 pM IL-5-stimulated
eosinophils to resting HUVEC was 16.6 ± 2.1% in the
absence of tulobuterol , which was higher than the
rate of spontaneous adhesion of eosinophils to rest-
ing HUVEC, and 15.8 ± 2 and 13.1 ± 1.7% in the pres-
ence of tulobuterol at concentrations of 10 and 100
nM, respectively(Fig. 3) . The decrease at 100 nM
was statistically significant ( p < 0.01, n = 9)．
When eosinophils were stimulated with FMLP, the
percentage of eosinophils adhering to resting HU-
VEC was 16.3 ± 4.1% in the absence of tulobuterol and
13.7 ± 3.7% and 12.7 ± 3.2% in the presence of tu-
lobuterol at concentrations of 10 and 100 nM (Fig. 4).
The decrease at 100 nM was statistically significant (
p < 0.01, n = 9)．
EFFECT OF TULOBUTEROL ON THE EX-
PRESSION OF ADHESION MOLECULES
We performed experiments using flow cytometry to
evaluate whether tulobuterol can modify surface ex-
pressions of CD11b, CD18 or VLA-4 on eosinophils.
The results confirmed that tulobuterol does not mod-
ify the surface expression of CD11b or CD 18 on
eosinophils in the presence of IL-5. (mean fluores-
cence index (M.F.I.) : CD11b, 577.4 ± 43.0 by control
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Fig. 3 The efect of tulobuterol on 100 pM IL-5-activated 
eosinophil adhesion to resting HUVEC. Administration was 
significantly atenuated by 100 nM tulobuterol (p<0.01). Val-
ues are the mean ± S.E.M. of nine experiments. 
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Fig. 4 The efect of tulobuterol on FMLP-activated eosino-
phil adhesion to resting HUVEC. Adhesion was significantly 
atenuated by 100 nM tulobuterol (p<0.01). Values are the 
mean ± S.E.M. of nine experiments. 
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vs. 592.4 ± 40.4 by tulobuterol, p > 0.1, n = 5, CD18,
1071.2 ± 62.6 by control vs. 1047.6 ± 50.6 by tu-
lobuterol, p > 0.1, n = 5). Similarly, turobuterol dose
not modify the expression of VLA-4 (CD49d ) on
eosinophils (35.7 ± 6.7 by control vs. 37.0 ± 8.5 by tu-
lobuterol, p > 0.1, n = 3)．
We also performed experiments employing a cell-
ELISA to determine whether tulobuterol modulates
the expression of ICAM-1 or VCAM-1 on endothelial
cells. The results confirmed that tulobuterol does not
modify the surface expression of adhesion molecules
on endothelial cells stimulated by IL-4 + TNF-α (O.
D. : ICAM-1, 0.36 ± 0.06 by control vs. 0.36 ± 0.06 by
tulobuterol, p > 0.1, n = 9, VCAM-1, 0.18 ± 0.04 by
control vs. 0.18 ± 0.04 by tulobuterol, p > 0.1, n = 9)．
DISCUSSION
In the present study, tulobuterol significantly inhib-
ited the spontaneous adhesion of peripheral blood
eosinophils to vascular endothelial cells stimulated
with IL-4 + TNFα. Tulobuterol also inhibited the ad-
hesion of eosinophils stimulated with IL-5 or FMLP to
resting vascular endothelial cells at concentrations
nearly equivalent to those expected in patients using
tulobuterol patches for clinical treatment . 10 These
findings suggest that tulobuterol inhibits the adhe-
sion of eosinophils to vascular endothelial cells by af-
fecting either integrin molecules of eosinophils or ad-
hesion molecules of vascular endothelial cells or
both.
In this study, both eosinophils and vascular endo-
thelial cells were treated with tulobuterol to investi-
gate the significance of use of tulobuterol in the clini-
cal setting. Both eosinophils and vascular endothelial
cells express β2-receptors.11,12 It has been reported
that β2-agonists inhibit degranulation, production of
LTC 4, and production of super oxide anions by
eosinophils.13,14 PDE inhibitors, a class of drugs in-
ducing increases in intracellular cyclic AMP level, an
effect also found with β2-agonists, have been demon-
strated to inhibit in vitro expression of ICAM-1 and
VCAM-1 by vascular endothelial cells.15 The authors
have reported that theophylline , which can inhibit
PDE activity and increase intracellular levels of cyclic
AMP , decreases both the adhesiveness of blood
eosinophils and the expression of VCAM-1 and
ICAM-1 on vascular endothelial cells in response to a
combination of IL-4 + TNFα.5 However, we confirmed
that tulobuterol does not modify the surface expres-
sion of adhesion molecules on eosinophils or endo-
thelial cells. We therefore speculate that tulobuterol
mainly modulates the functional status or conforma-
tional change of adhesion molecules . Another sys-
temic β2-agonists may exert similar inhibitory effects
on the adhesive interaction between eosinophils and
endothelial cells．
The inhibition of eosinophil adhesion to vascular
endothelial cells by tulobuterol observed in the pre-
sent study may involve interaction between α 4-
integrins of eosinophils and VCAM-1 of vascular en-
dothelial cells or interaction between β2-integrins of
eosinophils and ICAM-1 of vascular endothelial cell.
This hypothesis is based on the findings that HUVEC
stimulated with IL-4 + TNFα exhibits an increase in
adhesion to eosinophils mainly via interaction be-
tween α4-integrins of eosinophils and VCAM-1 of vas-
cular endothelial cells , 7,8 and that β 2-integrins of
eosinophils play an important role in mediating the
increase in adhesion of eosinophils by eosinophil
growth factors as well as FMLP.16 Further studies are
required to clarify the role of these adhesion mole-
cules in modifing the effect of tulobuterol on the ad-
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hesive interaction between eosinophils and endothe-
lial cells, and to examine whether β2-agonists other
than tulobuterol also exert the effects observed in the
present study．
The anti-inflammatory effect of tulobuterol ob-
served in the present study is likely to be of clinical
significance in the treatment of asthma when this
drug is administered systemically via transdermal
patches. Tulobuterol is expected to complement use
of corticosteroids which do not inhibit the adhesion
of eosinophils to vascular endothelial cells in vitro as
reported by the authors3 and Kaiser et al. 4 In fact,
Hozawa et al.17 reported that treatment with a combi-
nation of inhaled corticosteroid and tulobuterol
patches significantly decreased the number of eosino-
phils in sputum of adult patients with asthma, com-
pared with inhaled corticosteroid monotherapy.
Long-acting inhalational β2-agonists, including sal-
meterol , are not expected to exert the anti-
inflammatory effect observed with tulobuterol since
they are unlikely to modulate the functional status of
circulating eosinophils or the adhesiveness of endo-
thelial cells . Combined use of inhalational steroids
and salmeterol has been reported to yield a “masking
effect” on the airway inflammation associated with
asthma, as determined by measurement of numbers
of eosinophils in sputum or nitric oxide (NO) level in
expired air.18,19 Inhalational β2-agonists have potent
dilatative effects on airway smooth muscle, and are
also likely to affect epithelial cells in the airway as
well as T cells and eosinophils accumulating in air-
way tissues. In fact, β2-agonists inhibit the function of
T cells at high concentrations via selective effects on
Th1 cells. Panina-Bordigon et al. found that salbuta-
mol , a β2-agonist , inhibits the production of IL-12
from monocytes in a dose-related fashion.20 Huang et
al. reported that salbutamol decreases the Th1Th2
ratio of cord blood T cells.21 Malfait et al. showed that
salbutamol inhibited the production of IFN-γ in an ar-
thritis animal model.22 Taken together, these findings
suggest that inhalational β2-agonists may exacerbate
airway inflammation in patients with asthma by induc-
ing deterioration of the balance between Th1 and Th2
in sites of inflammation when local concentrations of
β2-agonist increase excessively in the airways . Re-
ports of exacerbation of eosinophil accumulation in
airway tissues by use of short-acting β2-agonists 23
mono-therapy and of exacerbation of airway hyper re-
sponsiveness to allergens by treatment with short-
acting β 2-agonists 24 suggest that inhalational β 2-
agonists have the potential to exacerbate allergic in-
flammation under certain conditions . Since tu-
lobuterol administered via transdermal patches does
not accumulate in high concentrations in the airways,
unfavorable effects would be expected to be mini-
mized. In general, β2-agonists have significant bron-
chodilatative effects even when administered systemi-
cally. In addition to their bronchodilatative effects, tu-
lobuterol patches are expected to inhibit the adhesion
of eosinophils to vascular endothelial cells. Treatment
with tulobuterol patches may thus be useful in con-
trolling allergic airway inflammation including eosino-
phil accumulation, the fundamental pathological fea-
ture of asthma . In conclusion , our study demon-
strated an inhibitory effect of tulobuterol, on the ad-
hesion of peripheral blood eosinophils to vascular en-
dothelial cells using a transdermal slow-releasing β2-
agonist patch widely used in Japan. Tulobuterol inhib-
ited the adhesion of eosinophils to endothelial cells
both when endothelial cells were stimulated with cy-
tokines to induce expression of adhesion molecules
and when surface molecules of eosinophils were
stimulated. The tulobuterol patch is thus expected to
act not only as a bronchodilator but also, possibly, as
a modulator of airway inflammation, the fundamental
pathological feature of asthma, in which accumulation
of eosinophils may be particularly important．
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